Stay updated on GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedFooter shows Revision: v3.3.2, replacing v3.2.0. This is a system version update and does not alter trial details or records.SummaryDifference0.1%

- Check28 days agoChange DetectedThe funding-delay notice on the page was removed, eliminating guidance about data currency during government funding gaps. This may reduce visibility into the page's reliability context for updates.SummaryDifference0.5%

- Check42 days agoChange DetectedBoth screenshots show the same Record History page for NCT03131908 with identical version entries and controls; any differences appear to be visual/UI adjustments rather than content updates.SummaryDifference0.1%

- Check71 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference11%

- Check78 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.3%

- Check92 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2. The 'Back to Top' element was removed.SummaryDifference0.6%

Stay in the know with updates to GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page.